In silico molecular docking studies of some phytochemicals against peroxisome-proliferator activated receptor gamma (PPAR-γ)

H. A  Ahmed; I. Y. Alkali

doi:10.30574/gscbps.2018.5.2.0085

Authors

H. A Ahmed Department of Pharmacognosy and Ethno pharmacy, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto- Nigeria.
I. Y. Alkali Department of Pharmacology and Toxicology, Usmanu Danfodiyo University, Sokoto- Nigeria.

DOI:

https://doi.org/10.30574/gscbps.2018.5.2.0085

Keywords:

Molecular docking, Phytochemicals, Pioglitazone, Peroxisome proliferator activated receptor gamma

Abstract

Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) is a ligand-activated transcription factor and a member of the nuclear receptor superfamily that regulate the gene expression of proteins involved in glucose, lipid metabolism, adipocyte proliferation and differentiation and insulin sensitivity. Thiazolidinediones (TZDs) are one important class of synthetic agonists of PPAR-γ. TZDs are antidiabetic agents that target adipose tissue and improve insulin sensitivity, and they are currently being used in the treatment of type 2 diabetes. The study was carried out in order to discover new phytochemicals that have the ability to stimulate the PPAR-γ using molecular docking studies. AutoDock vina was used as molecular-docking tool in order to carry out the docking simulations. Nine phytochemicals namely plumbagin, quercetin, isovitexin, mangiferin, syringin, lupe-20-ene-3-one, purine 2, 6-dione, diosmetin and β sitosterol and pioglitazone a standard drug were docked against PPAR-γ using AutoDock vina and the results were analyzed using binding affinity. The results revealed that the compounds have significant binding affinity towards the PPAR-γ comparable to pioglitazone the standard drug. Based on the findings of this study these phytochemicals can serve as source of antidiabetic drugs via the mechanism of agonizing of PPAR-γ.

Metrics

Metrics Loading ...

References

Umar A, Ahmed QU, Muhammad BY, Dogarai BB and Soad SZ. (2010). Antihyperglycemic activity of the leaves of Tetracera scandens Linn. Merr. (Dilleniaceae) in alloxan induced diabetic rats. Journal of Ethnopharmacology, 131, 140–145.

Moller DE. (2001). New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 414, 821-827.

Berger J and Moller DE. (2002). The mechanisms of action of PPARs. Annual Review Medicine, 53, 409–435.

Willson TM, Lambert MH and Kliewer SA. (2001). Peroxisome proliferator-activated receptor γ and metabolic disease. Annual Review Biochemistry, 70, 341.

Garcia-Vallvé S, Guasch L, Tomas-Hernández S, del Bas JM, Ollendorff V, Arola L, Pujadas G, Mulero M. (2015). Peroxisome proliferator-activated receptor γ (PPARγ) and ligand choreography: Newcomers Take the Stage: Miniperspective. Journal of medicinal chemistry, 58(14), 5381-5394.

Feldman PL, Lambert MH and Henke BR. (2008). PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Current topics in medicinal chemistry, 8(9), 728-749.

Bailey CJ and Day C. (2004) Metformin: its botanical background. Practical Diabetes International Journal, 21, 115-117.

David B, Wolfender JL and Dias DA. (2015). The pharmaceutical industry and natural products: Historical status and new trends. Phytochemistry Review, 14(2), 299-315.

Newman DJ and Cragg GM. (2016). Natural products as sources of new drugs from 1981 to 2014. Journal of natural products, 79(3), 629-661.

Schoichet BK. (2004). Virtual screening of chemical libraries. Nature, 43, 862-65.

Koppen H. (2009). Virtual screening: What does it give us? Current Opinion Drug Discovery Development, 12, 397-407.

Collignon B, Schulz R and Smith JC. (2011).Task-parallel message passing interface implementation of AutoDock4 for docking of very large databases of compounds using high-performance super-computers. Journal of Computational Chemistry, 32, 1202-09.

Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS and Olson AJ. (2010). Virtual Screening with AutoDock: Theory and practice. Expert Opinion Drug Discovery, 5, 597-607.

Alberg DG and Schreiber SL. (1993). Structure-based design of a cyclophilin– calcineurin bridging ligand. Science, 262, 248–250

Munhoz A and Frode TS. (2018). Isolated compounds from natural products with potential antidiabetic activity-A systematic review. Current diabetes reviews, 14(1), 36-106.

Berman HM. (2008). The protein data bank: A historical perspective. Acta Crystallographica Section A: Foundations of Crystallography, 64, 88-95.

Subramani PA, Panati K and Narala VR. (2013). Molecular docking of glyceroneogenesis pathway intermediates with peroxisome proliferator-activated receptor-alpha (PPAR-α). Bioinformation, 9(12), 629.

Srinivasan P, Vijayakumar S, Kothandaraman S and Palani M. (2018). Anti-diabetic activity of quercetin extracted from Phyllanthus emblica L. fruit: In silico and in vivo approaches. Journal of pharmaceutical analysis, 8(2), 109-118.

Amran MS, Sultan MZ, Rahman A and Rashid MA. (2013) Antidiabetic activity of compounds isolated from the kernel of Mangifera indica in alloxan induced diabetic rats. Dhaka University Journal of Pharmaceutical Sciences, 12, 77-81.

Folador P, Cazarolli LH, Gazola AC, Reginatto FH, Schenkel EP, Silva FRMB. (2010). Potential insulin secretagogue effects of isovitexin and swertisin isolated from Wilbrandia ebracteata roots in non-diabetic rats. Fitoterapia, 81(8), 1180-1187.

Kumar D, Ghosh R and Pal BC. (2013). Glucosidase inhibitory terpinoids from Potentilla fulgens and their quantitative estimation by validated HPLC method. J Funct Foods, 5(3), 1135-41.

Luo CT, Zheng H, Mao SS, Yang M, Luo C, Chen H. (2013). Xanthones from Swertia mussotii and their glycosidase inhibitory activities. Planta Med, 80, 201-8.

Shababa WN, Mohammad AHT, Tanvir IS, Asadul H, Saima S, Muntasir M, Risan P, Abu HMS, Mohuya M and Arkajyoti P. (2018). In silico docking studies of some isolated compounds of Clausena lansium (Lou.) against diabetic activity. Journal of Pharmacology and Clinical Toxicology, 6(1), 1100.